New Open Source AI Platform Aims To Accelerate Malaria Drug Discovery
New Open Source AI Platform Aims To Accelerate Malaria Drug Discovery
Publish Date: 2026-03-31 05:29:00
Source Domain: healthpolicy-watch.news
A health worker in Gyabankrom, Ghana, prepares a malaria vaccine.
” data-image-caption=”
A health worker in Gyabankrom, Ghana, prepares a malaria vaccine.
” data-medium-file=”https://i0.wp.com/healthpolicy-watch.news/wp-content/uploads/2026/03/Malaria-Vaccine.jpg?fit=300%2C200&ssl=1″ data-large-file=”https://i0.wp.com/healthpolicy-watch.news/wp-content/uploads/2026/03/Malaria-Vaccine.jpg?fit=640%2C427&ssl=1″ class=”size-full wp-image-132723″ alt=”A health worker in Gyabankrom, Ghana, prepares a malaria vaccine.” width=”1000″ height=”667″ srcset=”https://healthpolicy-watch.news/wp-content/uploads/2026/03/Malaria-Vaccine.jpg 1000w, https://healthpolicy-watch.news/wp-content/uploads/2026/03/Malaria-Vaccine-300×200.jpg 300w, https://healthpolicy-watch.news/wp-content/uploads/2026/03/Malaria-Vaccine-768×512.jpg 768w” sizes=”(max-width: 1000px) 100vw, 1000px”/A health worker in Gyabankrom, Ghana, prepares a malaria vaccine.
Scientists working on new malaria drugs now have access to an open-access artificial intelligence (AI)-powered platform aimed at accelerating drug discovery, thanks to a partnership between Medicines for Malaria Venture (MMV) and deepmirror.
Drug Design for Global Health (dd4gh) uses “both predictive and generative AI to give researchers, especially those in the most resource-limited settings, access to cutting-edge technology that would otherwise be out of reach”, according to a media release from MMV.
The dd4gh platform was developed using input gathered during co‑creation workshops in Ghana and Switzerland with global drug discovery researchers.
Its AI models are trained on data sets from a wide range of studies conducted by global health researchers, enabling scientists to benefit from insights generated across multiple research efforts.
“At a time when the global health sector is facing significant constraints, dd4gh demonstrates the power of partnership,” said MMV CEO Dr Martin Fitchet. “By giving scientists in low and…
